Isamu Okamoto

Research output

Research output per year 1998 2010 2012 2013 2015 2017 2018 2019 2020 2021 2022

• 329 Article
• 16 Review article
• 9 Letter
• 3 Comment/debate
• 2 More
  • 1 Editorial
  • 1 Short survey

Research output per year

Research output per year

Search results

• 2018

  Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

  Papadimitrakopoulou, V. A., Wu, Y. L., Han, J. Y., Ahn, M. J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C. H., Bulusu, K. C., Laus, G., Collins, B., Barrett, J. C., Chmielecki, J. & Mok, T. S. K., Oct 1 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii741

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Anticancer drug treatment for advanced lung cancer with interstitial lung disease

  Otsubo, K., Okamoto, I., Hamada, N. & Nakanishi, Y., Jul 2018, In: Respiratory Investigation. 56, 4, p. 307-311 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Interstitial Lung Diseases 100%
  • Lung Neoplasms 72%
  • Pharmaceutical Preparations 37%
  • Drug Therapy 23%
  • Platinum 21%
  14 Citations (Scopus)

• Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients

  Anai, S., Iwama, E., Yoneshima, Y., Otsubo, K., Tanaka, K., Nakanishi, Y. & Okamoto, I., Dec 2018, In: Lung Cancer. 126, p. 156-161 6 p.

  Research output: Contribution to journal › Article › peer-review

  • UGT1A1 enzyme 100%
  • Small Cell Lung Carcinoma 67%
  • Etoposide 64%
  • Platinum 63%
  • Alleles 34%
  3 Citations (Scopus)

• Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers

  Akamine, T., Takada, K., Toyokawa, G., Kinoshita, F., Matsubara, T., Kozuma, Y., Haratake, N., Takamori, S., Hirai, F., Tagawa, T., Okamoto, T., Yoneshima, Y., Okamoto, I., Shimokawa, M., Oda, Y., Nakanishi, Y. & Maehara, Y., Mar 2018, In: Surgical Oncology. 27, 1, p. 88-94 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Small Cell Lung Carcinoma 100%
  • Blood Proteins 99%
  • C-Reactive Protein 98%
  • Ligands 78%
  • Lymphocytes 22%
  30 Citations (Scopus)

• Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup

  Kato, T., Lee, S., Cheng, Y., Lee, G. W., Lee, K., Luft, A., Trigo, J., Hui, R., Balint, B., Robinson, A., Okamoto, I., Gerstner, G. J., Paz-Ares, L., Li, X., Shentu, Y., Piperdi, B. & Tafreshi, A., Nov 1 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. ix151

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer

  Takamori, S., Toyokawa, G., Okamoto, I., Takada, K., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Mukae, N., Hirai, F., Tagawa, T., Oda, Y., Iwaki, T., Iihara, K., Nakanishi, Y. & Maehara, Y., Jan 2018, In: Anticancer research. 38, 1, p. 553-557 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Small Cell Lung Carcinoma 100%
  • Ligands 78%
  • Neoplasm Metastasis 69%
  • Apoptosis 68%
  • Brain 54%
  22 Citations (Scopus)

• CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

  Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., Okamoto, I., Leighl, N., Hodge, R., McKeown, A., Brown, A. P., Rukazenkov, Y., Ramalingam, S. S. & Vansteenkiste, J., Nov 20 2018, In: Journal of Clinical Oncology. 36, 33, p. 3290-3297 8 p.

  Research output: Contribution to journal › Article › peer-review

  • osimertinib 100%
  • ErbB Receptors 59%
  • Protein-Tyrosine Kinases 57%
  • Non-Small Cell Lung Carcinoma 56%
  • N 556 9%
  331 Citations (Scopus)

• Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

  Iwama, E., Nakanishi, Y. & Okamoto, I., Mar 4 2018, In: Expert Review of Anticancer Therapy. 18, 3, p. 267-276 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • ErbB Receptors 100%
  • Protein-Tyrosine Kinases 95%
  • Non-Small Cell Lung Carcinoma 93%
  • Mutation 29%
  • Patient Selection 22%
  12 Citations (Scopus)

• Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade

  Tanaka, K., Yanagihara, T., Ikematsu, Y., Inoue, H., Ota, K., Kashiwagi, E., Suzuki, K., Hamada, N., Takeuchi, A., Tatsugami, K., Eto, M., Ijichi, K., Oda, Y., Otsubo, K., Yoneshima, Y., Iwama, E., Nakanishi, Y. & Okamoto, I., Jul 17 2018, In: Oncotarget. 9, 55, p. 30587-30593 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Bronchoalveolar Lavage Fluid 100%
  • Pleural Effusion 97%
  • Pneumonia 74%
  • Clone Cells 73%
  • T-Cell Antigen Receptor 70%
  18 Citations (Scopus)

• Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer

  Otsubo, K., Seki, N., Nakanishi, Y. & Okamoto, I., Mar 1 2018, In: Annals of Oncology. 29, 3, p. 780-781 2 p.

  Research output: Contribution to journal › Letter › peer-review
  3 Citations (Scopus)

• Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

  Ide, M., Tanaka, K., Sunami, S., Asoh, T., Maeyama, T., Tsuruta, N., Nakanishi, Y. & Okamoto, I., Nov 2018, In: Thoracic Cancer. 9, 11, p. 1519-1521 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Nivolumab 100%
  • Idiopathic Pulmonary Fibrosis 88%
  • Adenocarcinoma of Lung 78%
  • Non-Small Cell Lung Carcinoma 26%
  • Pleurisy 19%
  15 Citations (Scopus)

• Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

  Kato, T., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Tao, L., Yu, W., Khaznadar, T., Tajima, K., Shibata, M., Seki, A. & Yamamoto, N., Feb 1 2018, In: Drug Safety. 41, 2, p. 229-237 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Erlotinib 100%
  • Erlotinib Hydrochloride 80%
  • Bevacizumab 70%
  • Non-Small Cell Lung Carcinoma 56%
  • Safety 53%
  39 Citations (Scopus)

• Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing

  Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., Goto, K., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., Dec 2018, In: Cancer Science. 109, 12, p. 3921-3933 13 p.

  Research output: Contribution to journal › Article › peer-review

  • High-Throughput Nucleotide Sequencing 100%
  • ErbB Receptors 99%
  • Protein-Tyrosine Kinases 94%
  • Afatinib 68%
  • Polymerase Chain Reaction 61%
  17 Citations (Scopus)

• Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer

  Kimura, S., Harada, T., Ijichi, K., Tanaka, K., Liu, R., Shibahara, D., Kawano, Y., Otsubo, K., Yoneshima, Y., Iwama, E., Nakanishi, Y. & Okamoto, I., Jun 2018, In: Lung Cancer. 120, p. 98-107 10 p.

  Research output: Contribution to journal › Article › peer-review

  • trkB Receptor 100%
  • Small Cell Lung Carcinoma 79%
  • Brain-Derived Neurotrophic Factor 75%
  • Phenotype 43%
  • Brain Neoplasms 11%
  16 Citations (Scopus)

• Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study

  Ryu, S., Hayashi, M., Aikawa, H., Okamoto, I., Fujiwara, Y. & Hamada, A., Jan 2018, In: British Journal of Pharmacology. 175, 1, p. 29-37 9 p.

  Research output: Contribution to journal › Article › peer-review

  • CH5424802 100%
  • Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry 70%
  • Anaplastic Lymphoma Kinase 61%
  • Neuroblastoma 59%
  • Heterografts 53%
  12 Citations (Scopus)

• Intrinsic and extrinsic regulation of PD-L2 expression by transcription factor STAT3 or c-FOS in oncogene-driven non-small cell lung cancer

  Shibahara, D., Tanaka, K., Iwama, E., Kubo, N., Ota, K., Azuma, K., Harada, T., Fujita, J., Nakanishi, Y. & Okamoto, I., Oct 1 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii423-viii424

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non–Small Cell Lung Cancer

  Shibahara, D., Tanaka, K., Iwama, E., Kubo, N., Ota, K., Azuma, K., Harada, T., Fujita, J., Nakanishi, Y. & Okamoto, I., Jul 2018, In: Journal of Thoracic Oncology. 13, 7, p. 926-937 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Oncogenes 100%
  • Non-Small Cell Lung Carcinoma 94%
  • Ligands 74%
  • Apoptosis 64%
  • MAP4 56%
  19 Citations (Scopus)

• Metastatic lung adenocarcinoma mimicking meningioma

  Yanagihara, T., Seki, N., Akio, H., Arimura, K., Suzuki, S. & Okamoto, I., 2018, In: Internal Medicine. 57, 7, p. 1057-1058 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial

  Akamatsu, H., Katakami, N., Okamoto, I., Kato, T., Kim, Y. H., Imamura, F., Shinkai, M., Hodge, R. A., Uchida, H. & Hida, T., Jun 2018, In: Cancer Science. 109, 6, p. 1930-1938 9 p.

  Research output: Contribution to journal › Article › peer-review

  • osimertinib 100%
  • ErbB Receptors 59%
  • Non-Small Cell Lung Carcinoma 56%
  • Pemetrexed 41%
  • Protein-Tyrosine Kinases 35%
  40 Citations (Scopus)

• Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples

  Kiura, K., Yoh, K., Katakami, N., Nogami, N., Kasahara, K., Takahashi, T., Okamoto, I., Cantarini, M., Hodge, R. & Uchida, H., Apr 2018, In: Cancer Science. 109, 4, p. 1177-1184 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • osimertinib 100%
  • ErbB Receptors 59%
  • Non-Small Cell Lung Carcinoma 56%
  • Cell Biology 54%
  • Mutation 29%
  4 Citations (Scopus)

• Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer

  for the FLAURA Investigators, Jan 11 2018, In: New England Journal of Medicine. 378, 2, p. 113-125 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • osimertinib 100%
  • Non-Small Cell Lung Carcinoma 56%
  • Confidence Intervals 29%
  • ErbB Receptors 19%
  • Protein-Tyrosine Kinases 19%
  2382 Citations (Scopus)

• PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

  Yoneshima, Y., Ijichi, K., Anai, S., Ota, K., Otsubo, K., Iwama, E., Tanaka, K., Oda, Y., Nakanishi, Y. & Okamoto, I., Apr 2018, In: Lung Cancer. 118, p. 36-40 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Adenocarcinoma of Lung 100%
  • Mutation 52%
  • Neoplasms 21%
  • Protein-Tyrosine Kinases 10%
  • pembrolizumab 7%
  60 Citations (Scopus)

• PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer

  Takamori, S., Takada, K., Toyokawa, G., Azuma, K., Shimokawa, M., Jogo, T., Yamada, Y., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Oct 2018, In: Anticancer research. 38, 10, p. 5897-5901 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Small Cell Lung Carcinoma 100%
  • Ligands 78%
  • Biomarkers 72%
  • Apoptosis 68%
  • Pharmaceutical Preparations 46%
  14 Citations (Scopus)

• Phase 1 study on safety and PK of rovalpituzumab tesirine (Rova-T) in Japanese patients with advanced, recurrent SCLC

  Tanaka, K., Udagawa, H., Akamatsu, H., Takeda, M., Kanda, S., Yasuda, I., Okubo, S., Wong, S., Scripture, C., Tamura, T. & Okamoto, I., Oct 1 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. vii57

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset

  Kiura, K., Imamura, F., Kagamu, H., Matsumoto, S., Hida, T., Nakagawa, K., Satouchi, M., Okamoto, I., Takenoyama, M., Fujisaka, Y., Kurata, T., Ito, M., Tokushige, K., Hatano, B. & Nishio, M., Apr 1 2018, In: Japanese journal of clinical oncology. 48, 4, p. 367-375 9 p.

  Research output: Contribution to journal › Article › peer-review

  • ceritinib 100%
  • Crizotinib 84%
  • Anaplastic Lymphoma Kinase 78%
  • Non-Small Cell Lung Carcinoma 52%
  • Drug Therapy 34%
  18 Citations (Scopus)

• Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer

  Kawano, Y., Sasaki, T., Yamaguchi, H., Hirano, K., Horiike, A., Satouchi, M., Hosokawa, S., Morinaga, R., Komiya, K., Inoue, K., Fujita, Y., Toyozawa, R., Kimura, T., Takahashi, K., Nishikawa, K., Kishimoto, J., Nakanishi, Y. & Okamoto, I., Nov 2018, In: Lung Cancer. 125, p. 136-141 6 p.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel 100%
  • Carboplatin 72%
  • Non-Small Cell Lung Carcinoma 57%
  • Radiotherapy 44%
  • Leukopenia 23%
  10 Citations (Scopus)

• Prediction of therapeutic effect of chemotherapy for NSCLC using dual-input perfusion CT analysis: Comparison among bevacizumab treatment, two- agent platinum-based therapy without bevacizumab, and other non- bevacizumab treatment groups

  Yabuuchi, H., Kawanami, S., Iwama, E., Okamoto, I., Kamitani, T., Sagiyama, K., Yamasaki, Y. & Honda, H., Feb 2018, In: Radiology. 286, 2, p. 685-695 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Bevacizumab 100%
  • Platinum 94%
  • Non-Small Cell Lung Carcinoma 80%
  • Therapeutic Uses 73%
  • Perfusion 67%
  10 Citations (Scopus)

• Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer

  Tanaka, K., Isse, K., Fujihira, T., Takenoyama, M., Saunders, L., Bheddah, S., Nakanishi, Y. & Okamoto, I., Jan 2018, In: Lung Cancer. 115, p. 116-120 5 p.

  Research output: Contribution to journal › Article › peer-review

  • delta protein 100%
  • Small Cell Lung Carcinoma 73%
  • rovalpituzumab tesirine 28%
  • Immunoconjugates 8%
  • Neoplasms 6%
  57 Citations (Scopus)

• Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer

  Takamori, S., Takada, K., Azuma, K., Jogo, Y., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Toyokawa, G., Hirai, F., Tagawa, T., Okamoto, I., Nakanishi, Y., Kawahara, A., Akiba, J., Oda, Y. & Maehara, Y., Oct 2018, In: Anticancer research. 38, 10, p. 5903-5907 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Small Cell Lung Carcinoma 100%
  • Ligands 63%
  • Apoptosis 55%
  • Lung Neoplasms 35%
  • Programmed Cell Death 1 Ligand 2 Protein 21%
  10 Citations (Scopus)

• Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma: A single-institution retrospective study

  Takada, K., Toyokawa, G., Azuma, K., Takamori, S., Jogo, T., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Nov 1 2018, In: In Vivo. 32, 6, p. 1541-1550 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Adenocarcinoma of Lung 100%
  • Fluorodeoxyglucose F18 98%
  • Ligands 66%
  • Tomography 63%
  • Retrospective Studies 62%
  4 Citations (Scopus)

• Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

  Okamoto, I., Morita, S., Tashiro, N., Imamura, F., Inoue, A., Seto, T., Yamamoto, N., Ohe, Y., Nakagawa, K. & Fukuoka, M., Mar 2018, In: Lung Cancer. 117, p. 14-19 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Small Cell Lung Carcinoma 100%
  • Mutation 62%
  • ErbB Receptors 35%
  • Protein-Tyrosine Kinases 33%
  • Survival 30%
  55 Citations (Scopus)

• Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay

  Kimura, S., Tanaka, K., Harada, T., Liu, R., Shibahara, D., Kawano, Y., Nakanishi, Y. & Okamoto, I., Nov 2018, In: Cancer Science. 109, 11, p. 3657-3661 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Afatinib 100%
  • ErbB Receptors 62%
  • Mutation 36%
  • Protein-Tyrosine Kinases 25%
  • Non-Small Cell Lung Carcinoma 12%
  9 Citations (Scopus)

• Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis

  Otsubo, K., Kishimoto, J., Kenmotsu, H., Minegishi, Y., Ichihara, E., Shiraki, A., Kato, T., Atagi, S., Horinouchi, H., Ando, M., Kondoh, Y., Kusumoto, M., Ichikado, K., Yamamoto, N., Nakanishi, Y. & Okamoto, I., Jan 2018, In: Clinical Lung Cancer. 19, 1, p. e5-e9

  Research output: Contribution to journal › Article › peer-review

  • Albumin-Bound Paclitaxel 100%
  • nintedanib 99%
  • 130-nm albumin-bound paclitaxel 96%
  • Idiopathic Pulmonary Fibrosis 75%
  • Carboplatin 69%
  36 Citations (Scopus)
• 2017

  Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations

  Tanaka, K., Nosaki, K., Otsubo, K., Azuma, K., Sakata, S., Ouchi, H., Morinaga, R., Wataya, H., Fujii, A., Nakagaki, N., Tsuruta, N., Takeshita, M., Iwama, E., Harada, T., Nakanishi, Y. & Okamoto, I., Sep 15 2017, In: Oncotarget. 8, 40, p. 68123-68130 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Afatinib 100%
  • ErbB Receptors 62%
  • Protein-Tyrosine Kinases 59%
  • Non-Small Cell Lung Carcinoma 58%
  • Mutation 36%
  51 Citations (Scopus)

• Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

  Iwama, E., Goto, Y., Murakami, H., Harada, T., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Okazaki, A., Akamatsu, H., Morinaga, R., Ushijima, S., Shimose, T., Tokunaga, S., Hamada, A., Yamamoto, N., & 3 othersNakanishi, Y., Sugio, K. & Okamoto, I., Jul 2017, In: Journal of Thoracic Oncology. 12, 7, p. 1161-1166 6 p.

  Research output: Contribution to journal › Article › peer-review

  • CH5424802 100%
  • Non-Small Cell Lung Carcinoma 53%
  • Lung 31%
  • Crizotinib 12%
  • Anaplastic Lymphoma Kinase 11%
  30 Citations (Scopus)

• A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study

  Hayashi, H., Chiba, Y., Sakai, K., Fujita, T., Yoshioka, H., Sakai, D., Kitagawa, C., Naito, T., Takeda, K., Okamoto, I., Mitsudomi, T., Kawakami, Y., Nishio, K., Nakamura, S., Yamamoto, N. & Nakagawa, K., Nov 2017, In: Clinical Lung Cancer. 18, 6, p. 719-723 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Nivolumab 100%
  • Pemetrexed 96%
  • erbB-1 Genes 96%
  • Carboplatin 82%
  • Protein-Tyrosine Kinases 66%
  14 Citations (Scopus)

• CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment

  Kawano, Y., Iwama, E., Tsuchihashi, K., Shibahara, D., Harada, T., Tanaka, K., Nagano, O., Saya, H., Nakanishi, Y. & Okamoto, I., Nov 2017, In: Lung Cancer. 113, p. 72-78 7 p.

  Research output: Contribution to journal › Article › peer-review

  • erbB-1 Genes 100%
  • Oxidation-Reduction 73%
  • Non-Small Cell Lung Carcinoma 68%
  • Reactive Oxygen Species 38%
  • Cisplatin 25%
  8 Citations (Scopus)

• Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

  Ogata, H., Okamoto, I., Yoshimoto, G., Obara, T., Ijichi, K., Iwama, E., Harada, T., Akashi, K. & Nakanishi, Y., Mar 1 2017, In: Respiratory Investigation. 55, 2, p. 181-183 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelomonocytic, Chronic 100%
  • Blast Crisis 92%
  • erbB-1 Genes 89%
  • Protein-Tyrosine Kinases 62%
  • Non-Small Cell Lung Carcinoma 61%
  1 Citation (Scopus)

• Combination therapy with molecularly targeted agents in lung cancer

  Okamoto, I., Oct 2017, In: Annals of Oncology. 28, p. ix5

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer

  Takamori, S., Toyokawa, G., Okamoto, I., Takada, K., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Katsura, M., Mukae, N., Shoji, F., Okamoto, T., Oda, Y., Iwaki, T., Iihara, K., Nakanishi, Y. & Maehara, Y., Aug 2017, In: Anticancer research. 37, 8, p. 4223-4228 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Small Cell Lung Carcinoma 100%
  • Ligands 78%
  • Apoptosis 68%
  • Radiotherapy 22%
  • Jejunum 17%
  29 Citations (Scopus)

• Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))

  Vansteenkiste, J., Reungwetwattana, T., Nakagawa, K., Cho, B. C., Dols, M. A. C., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., Okamoto, I., Leighl, N., Hodge, R., McKeown, A., Brown, A. P., Rukazenkov, Y. & Ramalingam, S., Nov 2017, In: Annals of Oncology. 28, p. x196

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • osimertinib 100%
  • S 10 97%
  • Standard of Care 60%
  • Names 59%
  • Non-Small Cell Lung Carcinoma 56%
  11 Citations (Scopus)

• Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1

  Ikematsu, Y., Yoneshima, Y., Ijichi, K., Tanaka, K., Harada, T., Oda, Y., Nakanishi, Y. & Okamoto, I., Oct 2017, In: Lung Cancer. 112, p. 230-231 2 p.

  Research output: Contribution to journal › Letter › peer-review
  22 Citations (Scopus)

• Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies

  Okamoto, I., Schuette, W. H. W., Stinchcombe, T. E., Rodrigues-Pereira, J., San Antonio, B., Chen, J., Liu, J., John, W. J. & Zinner, R. G., May 4 2017, In: Current Medical Research and Opinion. 33, 5, p. 937-941 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Pemetrexed 100%
  • Carboplatin 85%
  • Non-Small Cell Lung Carcinoma 67%
  • Meta-Analysis 56%
  • Thrombocytopenia 47%
  4 Citations (Scopus)

• Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

  Iwama, E., Sakai, K., Azuma, K., Harada, T., Harada, D., Nosaki, K., Hotta, K., Ohyanagi, F., Kurata, T., Fukuhara, T., Akamatsu, H., Goto, K., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., Jan 1 2017, In: Annals of Oncology. 28, 1, p. 136-141 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Afatinib 100%
  • Cell-Free Nucleic Acids 82%
  • Adenocarcinoma of Lung 70%
  • High-Throughput Nucleotide Sequencing 62%
  • ErbB Receptors 62%
  58 Citations (Scopus)

• Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer

  Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H. & Nakanishi, Y., Jun 1 2017, In: Lung Cancer. 108, p. 75-82 8 p.

  Research output: Contribution to journal › Article › peer-review

  • erbB-1 Genes 100%
  • Non-Small Cell Lung Carcinoma 68%
  • Alleles 55%
  • Mutation 42%
  • Protein-Tyrosine Kinases 17%
  29 Citations (Scopus)

• Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)

  Fukuda, M., Shimada, M., Kitazaki, T., Nagashima, S., Hashiguchi, K., Ebi, N., Takayama, K., Nakanishi, Y., Semba, H., Harada, T., Seto, T., Okamoto, I., Ichinose, Y. & Sugio, K., Jan 1 2017, In: Thoracic Cancer. 8, 1, p. 40-45 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Irinotecan 100%
  • Lung Neoplasms 67%
  • Lung 45%
  • Maximum Tolerated Dose 37%
  • Glucuronosyltransferase 13%
  4 Citations (Scopus)

• Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer

  Otsubo, K., Nosaki, K., Imamura, C. K., Ogata, H., Fujita, A., Sakata, S., Hirai, F., Toyokawa, G., Iwama, E., Harada, T., Seto, T., Takenoyama, M., Ozeki, T., Mushiroda, T., Inada, M., Kishimoto, J., Tsuchihashi, K., Suina, K., Nagano, O., Saya, H., & 2 othersNakanishi, Y. & Okamoto, I., Sep 2017, In: Cancer Science. 108, 9, p. 1843-1849 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Pemetrexed 100%
  • Sulfasalazine 98%
  • Cisplatin 68%
  • Non-Small Cell Lung Carcinoma 67%
  • Neoplastic Stem Cells 26%
  28 Citations (Scopus)

• Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer

  Ogata, H., Yamamoto, Y., Harada, T., Nakanishi, Y., Okamoto, I., Iwama, E., Iwama, E., Kato, K. & Oda, Y., May 2017, In: Journal of Thoracic Oncology. 12, 5, p. e46-e47

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  4 Citations (Scopus)

• Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

  Yoneshima, Y., Morita, S., Ando, M., Miura, S., Yoshioka, H., Abe, T., Kato, T., Kondo, M., Hosomi, Y., Hotta, K., Yamamoto, N., Kishimoto, J., Nakanishi, Y. & Okamoto, I., Jan 1 2017, In: Clinical Lung Cancer. 18, 1, p. 100-103 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Albumin-Bound Paclitaxel 100%
  • 130-nm albumin-bound paclitaxel 96%
  • Docetaxel 69%
  • Non-Small Cell Lung Carcinoma 55%
  • Nanoparticles 55%
  6 Citations (Scopus)

• Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment

  Yanagihara, T., Tanaka, K., Ota, K., Kashiwagi, E., Takeuchi, A., Tatsugami, K., Eto, M., Nakanishi, Y. & Okamoto, I., Aug 1 2017, In: Annals of Oncology. 28, 8, p. 2038-2039 2 p.

  Research output: Contribution to journal › Letter › peer-review
  11 Citations (Scopus)